ENGN
enGene Holdings Inc.
Biotechnology
Market Cap$83M
5Y Perf.-78.9%
Build Your Comparison
Side-by-side financial analysisENGN
ALNY
NTLA
BEAM
Try popular comparisons:
Stock Comparison
ENGN vs ALNY vs NTLA vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$37.74B
5Y Perf.+68.1%
NTLA
Intellia Therapeutics, Inc.
Biotechnology
Market Cap$1.36B
5Y Perf.-59.1%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$2.98B
5Y Perf.+3.4%
ENGN vs ALNY vs NTLA vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ENGN |  ALNY |  NTLA |  BEAM |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $83M | $37.74B | $1.36B | $2.98B |
| Revenue (TTM) | — | $4.29B | $66M | $132M |
| Net Income (TTM) | $-122M | $577M | $-395M | $-65M |
| Gross Margin | — | 80.9% | -31.9% | -64.2% |
| Operating Margin | — | 17.5% | -6.4% | -281.0% |
| Forward P/E | — | 37.7x | — | — |
| Total Debt | $32M | $1.28B | $93M | $294M |
| Cash & Equiv. | $50M | $1.66B | $155M | $295M |
ENGN vs ALNY vs NTLA vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ENGN
ALNY
NTLA
BEAM
| Stock | Nov 23 | Jun 26 | Return |
|---|---|---|---|
| enGene Holdings Inc. (ENGN) | 100 | 21.1 | -78.9% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 168.1 | +68.1% |
| Intellia Therapeuti… (NTLA) | 100 | 40.9 | -59.1% |
| Beam Therapeutics I… (BEAM) | 100 | 103.4 | +3.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ENGN vs ALNY vs NTLA vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALNY leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ALNY emerged as the overall leader. Track its performance:
ENGN
enGene Holdings Inc.
The Income Pick
ENGN is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 2.26
Best for: income & stability
ALNY
Alnylam Pharmaceuticals, Inc.
The Long-Run Compounder
ALNY carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 366.4% 10Y total return vs BEAM's 54.8%
- 13.5% margin vs NTLA's -6.0%
- Beta 0.60 vs NTLA's 2.28
- 11.8% ROA vs NTLA's -46.1%, ROIC 33.4% vs -44.0%
Best for: long-term compounding
NTLA
Intellia Therapeutics, Inc.
The Secondary Option
NTLA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- Lower volatility, beta 2.18, Low D/E 23.7%, current ratio 13.09x
- Beta 2.18, current ratio 13.09x
- 120.0% revenue growth vs ENGN's -77.3%
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  BEAM | 120.0% revenue growth vs ENGN's -77.3% |
| Quality / Margins |  ALNY | 13.5% margin vs NTLA's -6.0% |
| Stability / Safety | ALNY | Beta 0.60 vs NTLA's 2.28 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | BEAM | +66.5% vs ENGN's -50.2% |
| Efficiency (ROA) | ALNY | 11.8% ROA vs NTLA's -46.1%, ROIC 33.4% vs -44.0% |
ENGN vs ALNY vs NTLA vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
Segment breakdown not available.
ENGN vs ALNY vs NTLA vs BEAM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALNYLAGGINGBEAM
Who Leads Where
ALNY leads in 3 of 6 categories
ENGN leads 0 • NTLA leads 0 • BEAM leads 0 • 2 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
NTLAIntellia Therapeutics…
0leads
ENGNenGene Holdings Inc.
0leads
ALNYAlnylam Pharmaceutica…
3leads
6 Total Categories
CATEGORYLEADERvs ENGNvs NTLAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALNY6/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALNY7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ALNY4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALNY leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY is the larger business by revenue, generating $4.3B annually — 64.9x NTLA's $66M. ALNY is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to NTLA's -6.0%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… |  NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | — | $4.3B | $66M | $132M |
| EBITDAEarnings before interest/tax | -$127M | $677M | -$411M | -$355M |
| Net IncomeAfter-tax profit | -$122M | $577M | -$395M | -$65M |
| Free Cash FlowCash after capex | -$104M | $641M | -$364M | -$384M |
| Gross MarginGross profit ÷ Revenue | — | +80.9% | -31.9% | -64.2% |
| Operating MarginEBIT ÷ Revenue | — | +17.5% | -6.4% | -2.8% |
| Net MarginNet income ÷ Revenue | — | +13.5% | -6.0% | -49.2% |
| FCF MarginFCF ÷ Revenue | — | +15.0% | -5.5% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +96.4% | -9.5% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +8.3% | +4.4% | +26.4% | +26.6% |
ALNY leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ENGN and ALNY and BEAM each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $83M | $37.7B | $1.4B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $65M | $37.4B | $1.3B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.71x | 121.39x | -3.18x | -35.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 37.74x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 67.05x | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 10.16x | 20.08x | 21.34x |
| Price / BookPrice ÷ Book value/share | 0.49x | 48.27x | 1.95x | 2.32x |
| Price / FCFMarket cap ÷ FCF | — | 81.09x | — | — |
Evenly matched — ENGN and ALNY and BEAM each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ALNY leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALNY delivers a 98.3% return on equity — every $100 of shareholder capital generates $98 in annual profit, vs $-57 for NTLA. NTLA carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 1.62x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs ENGN's 1/9, reflecting solid financial health.
| Metric | ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -55.8% | +98.3% | -57.3% | -5.9% |
| ROA (TTM)Return on assets | -45.7% | +11.8% | -46.1% | -4.6% |
| ROICReturn on invested capital | -67.4% | +33.4% | -44.0% | -31.1% |
| ROCEReturn on capital employed | -50.7% | +15.3% | -48.5% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 6 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.19x | 1.62x | 0.14x | 0.24x |
| Net DebtTotal debt minus cash | -$18M | -$379M | -$62M | -$1M |
| Cash & Equiv.Liquid assets | $50M | $1.7B | $155M | $295M |
| Total DebtShort + long-term debt | $32M | $1.3B | $93M | $294M |
| Interest CoverageEBIT ÷ Interest expense | -40.18x | 2.02x | — | 1.08x |
ALNY leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ALNY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $16,972 today (with dividends reinvested), compared to $810 for ENGN. Over the past 12 months, BEAM leads with a +66.5% total return vs ENGN's -50.2%. The 3-year compound annual growth rate (CAGR) favors ALNY at 13.6% vs ENGN's -56.7% — a key indicator of consistent wealth creation.
| Metric | ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -81.7% | -29.3% | +31.5% | +7.0% |
| 1-Year ReturnPast 12 months | -50.2% | -7.2% | +45.0% | +66.5% |
| 3-Year ReturnCumulative with dividends | -91.9% | +46.5% | -72.2% | -12.0% |
| 5-Year ReturnCumulative with dividends | -91.9% | +69.7% | -86.2% | -68.4% |
| 10-Year ReturnCumulative with dividends | -91.9% | +366.4% | -54.5% | +54.8% |
| CAGR (3Y)Annualised 3-year return | -56.7% | +13.6% | -34.8% | -4.2% |
ALNY leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALNY and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALNY is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than NTLA's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 79.7% from its 52-week high vs ENGN's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.26x | 0.60x | 2.28x | 2.18x |
| 52-Week HighHighest price in past year | $12.25 | $495.55 | $28.25 | $36.44 |
| 52-Week LowLowest price in past year | $1.40 | $281.76 | $7.95 | $15.60 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +57.1% | +42.9% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 44.0 | 43.4 | 48.4 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 1.0M | 6.3M | 1.9M |
Evenly matched — ALNY and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ENGN as "Hold", ALNY as "Buy", NTLA as "Buy", BEAM as "Buy". Consensus price targets imply 332.1% upside for ENGN (target: $7) vs 57.6% for ALNY (target: $446).
| Metric | ENGNenGene Holdings I… | ALNYAlnylam Pharmaceu… | NTLAIntellia Therapeu… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $445.67 | $26.29 | $48.00 |
| # AnalystsCovering analysts | 9 | 52 | 39 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALNY leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallAlnylam Pharmaceuticals, In… (ALNY)Leads 3 of 6 categories
Loading custom metrics...
ENGN vs ALNY vs NTLA vs BEAM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ENGN or ALNY or NTLA or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 16. 9% for Intellia Therapeutics, Inc. (NTLA). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 121. 4x trailing P/E (37. 7x forward), making it the more compelling value choice. Analysts rate Alnylam Pharmaceuticals, Inc. (ALNY) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ENGN or ALNY or NTLA or BEAM?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +69. 7%, compared to -91. 9% for enGene Holdings Inc. (ENGN). Over 10 years, the gap is even starker: ALNY returned +366. 4% versus ENGN's -91. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ENGN or ALNY or NTLA or BEAM?
By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.
(ALNY) is the lower-risk stock at 0. 60β versus Intellia Therapeutics, Inc. 's 2. 28β — meaning NTLA is approximately 277% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ENGN or ALNY or NTLA or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus 16. 9% for Intellia Therapeutics, Inc. (NTLA). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -56. 8% for enGene Holdings Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ENGN or ALNY or NTLA or BEAM?
Alnylam Pharmaceuticals, Inc.
(ALNY) is the more profitable company, earning 8. 4% net margin versus -609. 9% for Intellia Therapeutics, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -651. 7% for NTLA. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ENGN or ALNY or NTLA or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for ENGN: 332.
1% to $7. 00.
07Which pays a better dividend — ENGN or ALNY or NTLA or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ENGN or ALNY or NTLA or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), +366. 4% 10Y return). enGene Holdings Inc. (ENGN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +366. 4%, ENGN: -91. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ENGN and ALNY and NTLA and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ENGN is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock; NTLA is a small-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.